Hemabate

Hemabate is a prescription injectable medication whose active ingredient is carboprost tromethamine, supplied as an intramuscular solution. It belongs to the prostaglandin F2α analog class and is marketed in the European Union. Hemabate is used primarily as a uterotonic agent to promote uterine contraction in specific obstetric situations. The product is administered by a healthcare professional in a clinical setting. Administration follows established dosing protocols and monitoring guidelines.

Hemabate is indicated for the management of postpartum hemorrhage and related uterine conditions where rapid uterine contraction is required.

- Treatment of postpartum hemorrhage caused by uterine atony. - Control of bleeding after cesarean delivery when uterine tone is inadequate. - Management of severe postpartum bleeding unresponsive to oxytocin. - Adjunct therapy for uterine atony during surgical obstetric procedures. - Emergency use for refractory uterine bleeding when other uterotonics have failed. - Prevention of excessive uterine bleeding in high‑risk deliveries.

The safety profile of Hemabate includes both frequently observed and less common adverse reactions.

Common: - Abdominal or pelvic cramping. - Diarrhea or loose stools. - Nausea and occasional vomiting. - Fever or chills. - Headache or dizziness. - Injection site pain or erythema. - Transient tachycardia. - Mild hypertension.

Serious: - Severe allergic reaction (anaphylaxis) with rash, swelling, or breathing difficulty. - Significant hypotension or cardiovascular collapse. - Pulmonary edema or severe respiratory distress. - Massive hemorrhage due to uterine rupture. - Renal impairment. - Seizures. - Cardiac arrhythmias.

Before using Hemabate, healthcare providers should evaluate patient history and clinical status to minimize risks.

- Contraindicated in patients with known hypersensitivity to carboprost or other prostaglandin analogs. - Use with caution in individuals with asthma or severe respiratory disease, as bronchospasm may occur. - Avoid in patients with active cardiovascular disease, including hypertension or coronary artery disease. - Assess renal and hepatic function prior to administration, especially in patients with impairment. - Monitor for signs of uterine rupture or excessive uterine contraction during treatment. - Use only under direct medical supervision; not intended for self‑administration. - Consider alternative uterotonics if the patient is pregnant beyond the recommended gestational age for prostaglandin use.

Hemabate may interact with other medications, affecting efficacy or safety.

Avoid: - Concurrent use with other prostaglandin analogs (e.g., misoprostol) due to additive uterine effects. - Combination with non‑steroidal anti‑inflammatory drugs (NSAIDs) that increase risk of gastrointestinal bleeding. - Simultaneous administration with anticoagulants or antiplatelet agents that may exacerbate bleeding.

Use with caution: - Oxytocin or other uterotonics: may require dose adjustment to prevent overstimulation. - Beta‑agonist bronchodilators: monitor respiratory status in asthmatic patients. - Antihypertensive agents: observe blood pressure changes due to possible vasoconstriction. - Diuretics: watch for fluid balance alterations in patients with renal impairment.